blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3237015

EP3237015 - HYDROSOLUBLE HYDROXYBISPHOSPHONIC DOXORUBICINE DERIVATIVES [Right-click to bookmark this link]
Former [2017/44]HYDROSOLUBLE HYDROXYBISPHOSPHONIC DERIVATIVES OF DOXORUBICIN
[2018/33]
StatusNo opposition filed within time limit
Status updated on  06.03.2020
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  29.03.2019
FormerGrant of patent is intended
Status updated on  05.08.2018
FormerRequest for examination was made
Status updated on  29.09.2017
FormerThe international publication has been made
Status updated on  21.06.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Atlanthera
3, rue Aronnax
44800 Saint Herblain / FR
[2017/44]
Inventor(s)01 / EGOROV, Maxim
25 Chemin des Cantons
44340 Bouguenais / FR
02 / GOUJON, Jean-Yves
15 rue George Sand
44590 Derval / FR
03 / LE BOT, Ronan
11 rue Georges Claude
44100 Nantes / FR
04 / DAVID, Emmanuelle
3 La Charrie
44710 Port Saint Père / FR
 [2019/18]
Former [2017/44]01 / EGOROV, Maxim
25 chemin des Cantons
44340 Bouguenais / FR
02 / GOUJON, Jean-Yves
15 rue George Sand
44590 Derval / FR
03 / LE BOT, Ronan
11 rue Georges Claude
44100 Nantes / FR
04 / DAVID, Emmanuelle
3 La Charrie
44710 Port Saint Père / FR
Representative(s)IP Trust
2, rue de Clichy
75009 Paris / FR
[N/P]
Former [2017/44]Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
Application number, filing date15801727.720.11.2015
[2017/44]
WO2015EP77279
Priority number, dateFR2014006125320.11.2014         Original published format: FR 1461253
[2017/44]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2016079327
Date:26.05.2016
Language:FR
[2016/21]
Type: A1 Application with search report 
No.:EP3237015
Date:01.11.2017
Language:FR
The application published by WIPO in one of the EPO official languages on 26.05.2016 takes the place of the publication of the European patent application.
[2017/44]
Type: B1 Patent specification 
No.:EP3237015
Date:01.05.2019
Language:FR
[2019/18]
Search report(s)International search report - published on:EP26.05.2016
ClassificationIPC:A61K47/50, C07F9/38, C07C335/04, A61P19/00, A61P35/00
[2017/44]
CPC:
A61K31/663 (EP,US); A61K47/548 (EP,US); A61P19/00 (EP);
A61P19/08 (EP); A61P35/00 (EP); C07C335/40 (EP,US);
C07F9/6552 (EP,US); C07H15/244 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/44]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:WASSERLÖSLICHE BISPHOSPHONISCHE DOXORUBICINDERIVATE[2018/33]
English:HYDROSOLUBLE HYDROXYBISPHOSPHONIC DOXORUBICINE DERIVATIVES[2018/33]
French:DERIVES HYDROXYBISPHOSPHONIQUES HYDROSOLUBLES DE LA DOXORUBICINE[2017/44]
Former [2017/44]WASSERLÖSLICHE HYDROXYBISPHOSPHONDERIVATE VON DOXORUBICIN
Former [2017/44]HYDROSOLUBLE HYDROXYBISPHOSPHONIC DERIVATIVES OF DOXORUBICIN
Entry into regional phase20.06.2017National basic fee paid 
20.06.2017Designation fee(s) paid 
20.06.2017Examination fee paid 
Examination procedure20.06.2017Examination requested  [2017/44]
20.06.2017Date on which the examining division has become responsible
06.08.2018Communication of intention to grant the patent
21.01.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
15.03.2019Fee for grant paid
15.03.2019Fee for publishing/printing paid
15.03.2019Receipt of the translation of the claim(s)
Opposition(s)04.02.2020No opposition filed within time limit [2020/15]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
15.03.2019Request for further processing filed
15.03.2019Full payment received (date of receipt of payment)
Request granted
26.03.2019Decision despatched
Fees paidRenewal fee
14.05.2018Renewal fee patent year 03
28.11.2018Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.11.201703   M06   Fee paid on   14.05.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL01.05.2019
CY01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
MK01.05.2019
MT01.05.2019
RO01.05.2019
RS01.05.2019
SI01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
LU20.11.2019
[2022/31]
Former [2021/34]AL01.05.2019
CY01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
MT01.05.2019
RO01.05.2019
RS01.05.2019
SI01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
LU20.11.2019
Former [2021/26]AL01.05.2019
CY01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
SI01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
LU20.11.2019
Former [2020/35]AL01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
SI01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
LU20.11.2019
Former [2020/26]AL01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
SI01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
Former [2020/14]AL01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
SK01.05.2019
SM01.05.2019
BG01.08.2019
IS01.09.2019
Former [2020/11]AL01.05.2019
CZ01.05.2019
EE01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
SK01.05.2019
BG01.08.2019
IS01.09.2019
Former [2020/10]AL01.05.2019
CZ01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RO01.05.2019
RS01.05.2019
BG01.08.2019
IS01.09.2019
Former [2020/09]AL01.05.2019
CZ01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RS01.05.2019
BG01.08.2019
IS01.09.2019
Former [2020/04]AL01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RS01.05.2019
BG01.08.2019
IS01.09.2019
Former [2019/52]AL01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RS01.05.2019
BG01.08.2019
Former [2019/50]AL01.05.2019
HR01.05.2019
LT01.05.2019
LV01.05.2019
RS01.05.2019
Former [2019/47]LT01.05.2019
Cited inInternational search[A]WO9640156  (ELIZANOR BIOPHARMACEUTICALS IN [US]) [A] 1-14 * Voir les dérivés de la doxorubicine décrits dans le document *;
 [A]WO2009083614  (UNIV NANTES [FR], et al) [A] 1-14 * page 3, line 1 - line 31 * * Page 6, lignes 17, 26 "Doxorubicine" * * page 8, line 24 - page 9, line 3 * * page 31 - page 36 * * example - * * claim - *;
 [A]WO2009083613  (UNIV NANTES [FR], et al) [A] 1-14 * example -; claim -; compound - *;
 [A]WO2011023367  (KTB TUMORFORSCHUNGS GMBH [DE], et al) [A] 1-14 * page 3, line 20 - page 4, line 15 * * page 25; example 1 * * page 26; example 2; compound 6 * * claims 10-14 * * compounds XIII, XIV, XV * * figure 6 *;
 [A]WO2012130911  (ATLANTHERA [FR], et al) [A] 1-14 * page 1, lines 1-6 * * page 2, line 28 - page 3, line 10 * * page 4, line 29 - page 5, line 6 * * Pages 19, 62, 84: composé 94 * * page 23, line 14 - line 21 * * Page 50, composé 62 * * example -; claim - *;
 [A]  - HOCHDÖRFFER KATRIN ET AL, "Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.", JOURNAL OF MEDICINAL CHEMISTRY 13 SEP 2012, (20120913), vol. 55, no. 17, ISSN 1520-4804, pages 7502 - 7515, XP002736394 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm300493m
 [A]  - SCOZZAFAVA A ET AL, "Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 45, no. 7, doi:10.1021/JM0108202, ISSN 0022-2623, (20020328), pages 1466 - 1476, (20020222), XP002595850 [A] 1-14 * abstract * * page 1467, column 1 * * page 1471, column 1 * * page 1472, column 1 * * page 1473, column 2 *

DOI:   http://dx.doi.org/10.1021/JM0108202
 [A]  - KHOLOD ET AL., "Application of Quantum Chemical Approximations to Environmental Problems: Prediction of Water Solubility for Nitro Compounds", ENVIRONMENTAL SCIENCE & TECHNOLOGY, (200912), vol. 43, no. 24, doi:10.1021/ES902566B, ISSN 0013-936X, pages 9208 - 9215, XP002756683 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1021/ES902566B
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.